Albert Ruttinger, DO
Geriatric Medicine · Surprise, AZNPI 1740253434
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.8% of the total across 431 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 34 manufacturers reported payments, led by AstraZeneca at 34.2% of the total. Among geriatric medicine clinicians in AZ with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 431 payments — averaging $24.66 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$4K
- Lilly USA, LLC$984
- Amgen$886
- Abbott$572
- Boehringer Ingelheim$535
- Johnson & Johnson$352
- plus $4K from 28 others
What the payments were for
- Food & beverage$10,605100%
- Education$220%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 103 | $3,630 |
| Lilly USA, LLC | 59 | $984 |
| Amgen(2 entities) | 41 | $886 |
| Abbott | 20 | $572 |
| Boehringer Ingelheim | 33 | $535 |
| Johnson & Johnson | 29 | $352 |
| Boston Scientific | 5 | $347 |
| Kowa Pharmaceuticals America, Inc. | 26 | $341 |
| Bayer | 5 | $337 |
| Novartis | 13 | $299 |
| Novo Nordisk | 13 | $277 |
| Otsuka America Pharmaceutical, Inc. | 3 | $268 |
| AbbVie(2 entities) | 13 | $236 |
| Pfizer | 8 | $188 |
| GSK | 9 | $173 |
| Vertiflex, Inc. | 4 | $147 |
| Sanofi-aventis U.S. LLC | 8 | $141 |
| Edwards Lifesciences | 1 | $140 |
| Exact Sciences | 5 | $128 |
| Philips North America LLC | 5 | $103 |
| Lundbeck LLC | 4 | $77 |
| Esperion Therapeutics, Inc. | 4 | $67 |
| Medicure Pharma Inc. | 2 | $52 |
| Amarin Pharma, Inc. | 3 | $52 |
| Dexcom, Inc. | 3 | $49 |
| Nestle Healthcare Nutrition Inc. | 2 | $46 |
| Merck | 3 | $42 |
| Sumitomo Pharma America, Inc. | 1 | $26 |
| Medtronic | 1 | $25 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 1 | $25 |
| Biogen | 1 | $23 |
| Mylan Specialty L.p. | 1 | $23 |
| Xeris Pharmaceuticals, Inc. | 1 | $19 |
| GE HealthCare | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- BREZTRI$718
- AIRSUPRA$671
- FARXIGA$550
- Kerendia$265
- FreeStyle Libre 2$258
- REXULTI$242
- WATCHMAN FLX$142
- SAPIEN 3 Ultra RESILIA$140
- KRYSTEXXA$125
- Repatha$122
- KISUNLA$119
- Superion ISS$101
How this compares
$10,627 in reported general payments places this provider in the 90th percentile of 75 geriatric medicine providers in Arizona.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XareltoRivaroxaban | 127 | $138,548 |
| JardianceEmpagliflozin | 105 | $120,915 |
| TrulicityDulaglutide | 93 | $119,338 |
| FarxigaDapagliflozin Propanediol | 81 | $77,340 |
| OzempicSemaglutide | 56 | $76,629 |
| GlyxambiEmpagliflozin/Linagliptin | 49 | $61,328 |
| MounjaroTirzepatide | 43 | $57,732 |
| EliquisApixaban | 31 | $37,676 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 29 | $23,090 |
| Rosuvastatin Calcium | 1,103 | $17,126 |
| TradjentaLinagliptin | 13 | $12,521 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 15 | $11,466 |
| LivaloPitavastatin Calcium | 16 | $10,789 |
| Ezetimibe | 381 | $10,532 |
| MyrbetriqMirabegron | 15 | $8,248 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance, Glyxambi, Tradjenta | $535 | $194,764167 claims |
| Lilly USA, LLCTrulicity, Mounjaro, Olanzapine | $984 | $178,645223 claims |
| Johnson & JohnsonXarelto | $352 | $138,548127 claims |
| AstraZenecaFarxiga, Breztri Aerosphere | $3,630 | $100,430110 claims |
| Novo NordiskOzempic | $277 | $76,62956 claims |
| PfizerEliquis | $188 | $37,67631 claims |
| Kowa Pharmaceuticals America, Inc.Livalo | $341 | $10,78916 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 75 geriatric medicine providers in Arizona.
Other geriatric medicine in Surprise
- Rikesh DesaiSurprise$8K
- Paria PourmalekSurprise$291
- Dapinderjit GillSurprise$264
- John MiglianoTucson$100K
- Robin MacdougallPhoenix$51K
- John HomanTucson$18K
- Raghav MohindraPrescott Valley$16K
- Aureliano CifuentesTempe$8K
- Ramakrishnan SubbureddiarTucson$7K
- Anil NandaPhoenix$4K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.